Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection May 16th 2023 Read More
Shorla Oncology Announces U.S. FDA Approval of Nelarabine Injection for the Treatment of T-Cell Leukemia March 9th 2023 Read More
We were delighted to have been a presenting company at the BIOTECH Showcase 2023 in San Francisco recently! January 16th 2023 Read More
Join Shorla Oncology at the BIO CEO and Investor Conference 2023 January 17th 2023January 16th 2023 Read More
